Active ingredient
Ravulizumab
3 finished FDA listings contain Ravulizumab as their only active ingredient.
FDA NDC Directory
- Ingredient names as written by FDA
- RAVULIZUMAB, RAVULIZUMAB-CWVZ
- Dosage forms
- Solution, Concentrate
- Routes
- Intravenous
- Manufacturers / labelers
- 1
- Strengths listed
- 1100 mg/11ml · 300 mg/30ml · 300 mg/3ml
- Brand names in FDA listings
- Ultomiris
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 2107301
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| BLA 761108 | ALEXION PHARM | 2018-12-21 | 3 |
Official labeling on DailyMed
- ULTOMIRIS (RAVULIZUMAB) SOLUTION, CONCENTRATE [ALEXION PHARMACEUTICALS INC.] · version 19 · 2025-11-17
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.